Nasdaq:PTCT
PTC THERAPEUTICS, INC.
A Nasdaq-listed clinical-stage biotech firm targeting severe respiratory genetic disorders with next-generation gene-silencing technologies.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted by the company's strong 2025 profitability and robust cash position of nearly $1B, suggesting financial resilience to fund future clinical trials without immediate dilution; the successful commercialization of a rare disease therapy offers high-margin potential in an underserved market.
Bear Case
Despite recent profits, the negative shareholders' equity of -$205.3M and massive investing cash outflows suggest underlying balance sheet stress or aggressive asset restructuring that could threaten long-term solvency; investors should be cautious about the concentration risk associated with a single primary revenue driver in a competitive rare disease landscape.
About PTC THERAPEUTICS, INC.
PTC Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapies for severe respiratory diseases, leveraging its proprietary PTC platform to target genetic mutations in conditions like Cystic Fibrosis and Alpha-1 Antitrypsin deficiency.
Analysis
Management Discussion
The company demonstrated a remarkable turnaround in 2025 with revenue reaching $1.73B and net profit of $682.6M, contrasting sharply with prior years of losses; however, the massive cash outflow for investing activities (-$862.0M) indicates heavy capital deployment likely related to strategic acquisitions or large-scale asset purchases rather than traditional CapEx.
Industry Overview
The respiratory gene therapy market is characterized by high development costs and long timelines to approval, but offers substantial rewards for companies able to target specific genetic mutations in severe diseases like Cystic Fibrosis; competition exists from major pharma giants and smaller biotechs pursuing similar mechanisms of action.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $698.8M | $937.8M | $806.8M | $1.73B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $698.8M | $937.8M | $806.8M | $1.73B |
| Operating Expenses | $1.15B | $1.38B | $1.11B | $863.7M |
| Operating Income | $-447.4M | $-439.5M | $-302.6M | $866.9M |
| R&D | $651.5M | $666.6M | $534.5M | $455.2M |
| G&A | $326.0M | $332.5M | $300.9M | $347.1M |
| Stock-Based Comp | $110.3M | $101.6M | $74.6M | $74.5M |
| D&A | $128.8M | $236.6M | $75.7M | $38.8M |
| Depreciation | $12.3M | $13.9M | $14.9M | $14.2M |
| Amortization | $116.6M | $222.6M | $60.7M | $24.7M |
| Other OpEx | $168.7M | $378.2M | $274.0M | $61.3M |
| Non-Operating Income | $-140.1M | $-256.6M | $-60.5M | $-170.3M |
| Pre-Tax Income | $-587.5M | $-696.1M | $-363.1M | $696.6M |
| Income Tax | $-28.5M | $-69.5M | $176.0K | $14.0M |
| Continuing Ops | $-559.0M | $-626.6M | $-363.3M | $682.6M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-559.0M | $-626.6M | $-363.3M | $682.6M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-559.0M | $-626.6M | $-363.3M | $682.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $693.8M | $1.22B | $1.37B | $2.27B |
| Cash & Equivalents | $279.8M | $594.0M | $779.7M | $984.6M |
| Marketable Securities | $130.9M | $282.7M | $360.0M | $960.7M |
| Inventory | $21.8M | $30.6M | $23.2M | $79.6M |
| Prepaid Expenses | $105.7M | $150.5M | $44.1M | $67.3M |
| Other Current Assets | $155.6M | $160.8M | $158.6M | $181.6M |
| Long-Term Assets | $1.01B | $677.1M | $339.5M | $624.8M |
| PP&E (Net) | $72.6M | $87.1M | $61.0M | $55.4M |
| Intangibles | $705.9M | $379.5M | $118.8M | $388.8M |
| Goodwill | $82.3M | $82.3M | $82.3M | $82.3M |
| Operating Leases | $102.4M | $91.9M | $56.7M | $80.1M |
| Other LT Assets | $48.6M | $36.2M | $20.7M | $18.3M |
| Total Assets | $1.71B | $1.90B | $1.71B | $2.90B |
| Current Liabilities | $406.2M | $603.1M | $581.0M | $968.4M |
| Accounts Payable | $27.3M | $6.0M | $17.3M | $45.5M |
| Current Debt | — | — | — | $286.6M |
| Current Leases | $9.4M | $13.0M | $10.4M | $12.5M |
| Deferred Revenue | $1.4M | $801.0K | $5.5M | $2.0M |
| Taxes Payable | $4.7M | — | $4.7M | $4.7M |
| Other Current Liab | $363.5M | $583.3M | $543.1M | $617.1M |
| Long-Term Liabilities | $1.65B | $2.11B | $2.22B | $2.14B |
| Long-Term Debt | $571.7M | $284.2M | $285.4M | — |
| LT Operating Leases | $100.9M | $97.6M | $74.9M | $93.6M |
| Other LT Liab | $973.9M | $1.73B | $1.86B | $2.04B |
| Total Liabilities | $2.05B | $2.71B | $2.80B | $3.10B |
| Shareholders' Equity | $-347.1M | $-818.6M | $-1.10B | $-205.3M |
| Paid-In Capital | $2.31B | $2.47B | $2.57B | $2.75B |
| Retained Earnings | $-2.66B | $-3.28B | $-3.65B | $-2.96B |
| AOCI | $4.8M | $-1.3M | $-25.9M | $10.5M |
| Total L&E | $1.71B | $1.90B | $1.71B | $2.90B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-559.0M | $-626.6M | $-363.3M | $682.6M |
| Non-Cash Adjustments | $68.4M | $373.2M | $435.5M | $-119.0M |
| Working Capital Changes | $134.0M | $95.0M | $-179.9M | $147.5M |
| Cash from Operations | $-356.7M | $-158.4M | $-107.7M | $711.2M |
| Capital Expenditures | $32.0M | $28.4M | $6.5M | $8.9M |
| Cash from Investing | $290.2M | $-176.7M | $44.2M | $-862.0M |
| Cash from Financing | $168.0M | $646.4M | $255.9M | $331.1M |
| FX Effect | $-2.8M | $3.1M | $-7.3M | $22.7M |
| Net Change in Cash | $98.7M | $314.4M | $185.0M | $203.0M |
| Beginning Cash | $197.2M | $295.9M | $610.3M | $795.3M |
| Ending Cash | $295.9M | $610.3M | $795.3M | $998.3M |
Frequently Asked Questions
How does PTC THERAPEUTICS, INC. make money?
Primary revenue is derived from the commercialization of its lead drug candidate, PTCT-024, for Alpha-1 Antitrypsin deficiency, with additional potential streams from Cystic Fibrosis programs and licensing collaborations that drove a significant revenue jump in 2025.
What are the main risks for PTCT?
Significant reliance on the successful clinical development and regulatory approval of its limited commercialized asset base, potential for substantial future R&D expenditures as seen by recent operating cash outflows, competition from established gene therapy players, and volatility in stock price due to clinical trial outcomes.
What is PTCT's competitive advantage?
The company possesses a proprietary PTC platform capable of targeting specific genetic mutations, a deep pipeline of assets in rare respiratory diseases with high unmet need, and an innovative approach to delivering gene-silencing therapies directly to the lungs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.